EUCTR2014-000231-16-FI进行中（未招募）不适用
An interventional, randomised, double-blind, parallel-group,active-comparator, flexible-dose study on the efficacy ofvortioxetine versus escitalopram on cognitive dysfunction inpatients with inadequate response to current antidepressanttreatment of major depressive disorder
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- The patient has MDD, diagnosed according to DSM-IV-TR™ recurrent MDE (classification 296.3x) as confirmed using the Mini International Neuropsychiatric Interview (MINI).
- •- The patient has depressive symptoms currently considered as non- or only partially responsive (inadequate response), to one adequate course of SSRI/SNRI antidepressant monotherapy and is candidate for a switch in the investigator's opinion.
- •- The patient wants to stop taking his/her current SSRI/SNRI treatment due to inadequate response confirmed by the Antidepressant Treatment Response
- •Questionnaire (ATRQ), <50% response to current treatment).
- •- The patient must have been treated by SSRI/SNRI monotherapy (citalopram, paroxetine, sertraline, duloxetine, or venlafaxine) for at least 6 weeks at licensed doses prior to the Screening Visit.
- •- The patient has a PHQ-9 total score =14.
- •- The patient has a MADRS total score = 22.
- •- The patient has had the current MDE for =1 year.
- •- The patient has a Perceived Deficits Questionnaire - Depression (PDQ-D) total score >25.
- •- The patient is a man or woman aged =18 and =65 years.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- The patient has a score =70 on the DSST (Number of Correct Symbols) at the Baseline Visit.
- •- The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
- •- The patient has any current psychiatric disorder or Axis I disorder (according to DSMIV-TR™ criteria) other than MDD, as assessed using MINI.
- •- The patient has a current or has had a diagnosis of dysthymic disorder within 3 months preceding the onset of current episode (DSM-IV-TR™ criteria).
- •- The patient has borderline, schizotypal, schizoid, paranoid, histrionic, antisocial personality disorders (axis II) as comorbid or primary diagnosis (DSM-IV-TR™ criteria).
- •- The patient has history of previous MDEs considered as treatment resistant defined as inadequate response (incomplete or no therapeutic response) to two prior courses of at least 6 weeks of conventional antidepressant drugs in adequate dosages or, the patient has treatment-resistant depression in the investigator's judgement.
- •- The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
- •- The patient has a diagnosis of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) (DSM-IV-TR™ criteria) that has not been in
- •sustained full remission at least 2 years prior to the Screening Visit.
- •- The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM-IV-TR™ criteria).
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the cognitive effect of a product named vortioxetine (used in depression). These effects willbe compared to those induced by a marketed comparator and a placebo. Investigator and subjects will be blinded.EUCTR2014-000229-19-FIH. Lundbeck A/S195
进行中（未招募）
1 期
A study to evaluate the cognitive effect of a product named vortioxetine (used in depression). These effects willbe compared to those induced by a marketed comparator and a placebo. Investigator and subjects will be blinded.Major Depressive Disorder and cognitive impairmentMedDRA version: 17.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2014-000229-19-EEH. Lundbeck A/S195
进行中（未招募）
不适用
A study to evaluate the cognitive effect of a product named vortioxetine (used in depression) for patient with inadequate effect of other drugs for depression. These effects will be compared to those induced by a marketed comparator. Investigator and subjects will be blinded.Major Depressive Disorder and cognitive impairmentMedDRA version: 17.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2014-000231-16-DEH. Lundbeck A/S130
进行中（未招募）
不适用
A study to evaluate the cognitive effect of a product named vortioxetine (used in in depression). These effects will be compared to those induced by a marketed comparator and a placebo. Investigator and subjects will be blinded.EUCTR2014-000230-34-SKH. Lundbeck A/S195
进行中（未招募）
1 期
A study to evaluate the cognitive effect of a product named vortioxetine (used in depression). These effects willbe compared to those induced by a marketed comparator and a placebo. Investigator and subjects will be blinded.Major Depressive Disorder and cognitive impairmentMedDRA version: 17.0Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2014-000229-19-SKH. Lundbeck A/S195